



a concentration of 20 to 150 µg/ml.

- 5 7. The pharmaceutical combination according to any one of the preceding claims, wherein the pharmaceutical formulation (a) comprises lixisenatide in a concentration of 33 µg/mL, 50 µg/mL or 100 µg/mL.
- 10 8. The pharmaceutical combination according to any one of the preceding claims, wherein the pharmaceutical formulation (a) comprises insulin glargine in a concentration of 100 U/ml, and lixisenatide in a concentration of 33 µg/mL, 50 µg/mL or 100 µg/mL.
- 15 9. The pharmaceutical combination according to any one of the preceding claims, for use in the treatment of a type 2 diabetes mellitus patient.
10. The pharmaceutical combination for use according to claim 9, wherein the type 2 diabetes mellitus to be treated is not adequately controlled with the SGLT2 inhibitor alone.
- 20 11. The pharmaceutical combination for use according to claim 9 or 10, wherein the type 2 diabetes mellitus to be treated is not adequately controlled with an SGLT2 inhibitor and an oral anti-diabetic alone.
- 25 12. The pharmaceutical combination for use according to any one of the claims 9 to 11, wherein the type 2 diabetes mellitus to be treated is not adequately controlled with the SGLT2 inhibitor and metformin alone, or with an SGLT2 inhibitor and a GLP-1 receptor agonist alone.
- 30 13. The pharmaceutical combination for use according to any one of the claims 9 to 12, wherein the type 2 diabetes mellitus to be treated is not adequately controlled with the SGLT2 inhibitor, metformin and a GLP-1 receptor agonist alone.

14. The pharmaceutical combination for use according to claim 12 and 13, wherein the GLP-1 receptor agonist is selected from lixisenatide, exenatide, dulaglutide, and liraglutide.

5

15. The pharmaceutical combination for use according to any one of the claims 9 to 14, wherein the patient to be treated is obese.